MedTrace Logo

Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women

NCT07402382 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-13

No results posted yet for this study

Summary

The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period.

The main questions the study aims to answer are:

* Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance
* Can the affect be achieved using a concentrated dose

Researchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness.

Participants will:

* Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout
* Complete four in-person visits, including the single-day intervention

Results from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.

Conditions

  • Glucose Monitoring, Continuous
  • Whole Body Protein Metabolism
  • Peri-menopausal Women
  • Post-menopause

Interventions

DIETARY_SUPPLEMENT

Amylopectin-chromium blend

Amylopectin-chromium blend, 2 g

DIETARY_SUPPLEMENT

Concentrated Amylopectin-chromium blend

Amylopectin-chromium blend in a concentrated format (100 mg)

DIETARY_SUPPLEMENT

Placebo

Amylopectin, 2 g

Sponsors & Collaborators

  • The Center for Applied Health Sciences, LLC

    collaborator INDUSTRY

  • Nutrition 21, Inc.

    lead INDUSTRY

Principal Investigators

  • Tim Ziegenfuss, PhD · The Center for Applied Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07402382 on ClinicalTrials.gov